{"entity":{"id":"da-trial-engage","kind":"trial","name":"ENGAGE","aka":[],"tldr":"ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.","summary":"One of two large aducanumab trials. ENGAGE did not meet its primary endpoint. The later US accelerated approval was withdrawn. Failure trials belong in a map so positive trials are not the only story.","status":"negative","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT02477800","url":"https://clinicaltrials.gov/study/NCT02477800"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":["da-aducanumab"],"companies":["da-biogen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02477800","phase":"3","setting":"Early Alzheimer’s disease","sponsor":"Biogen","result":"Primary endpoint not met as designed. Historical context for aducanumab, which is not a current US option.","yearReported":2019,"enrolled":1647,"outcomes":[{"endpoint":"Primary clinical endpoint","primary":true,"arms":[{"name":"Aducanumab","note":"Did not meet the primary endpoint as designed"},{"name":"Placebo"}],"source":"https://clinicaltrials.gov/study/NCT02477800"}]},"route":"/trials/da-trial-engage/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"drug":[{"id":"da-aducanumab","kind":"drug","name":"Aducanumab","route":"/drugs/da-aducanumab/"}],"company":[{"id":"da-biogen","kind":"company","name":"Biogen","route":"/companies/da-biogen/"}],"roadmap":[{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","route":"/roadmaps/da-roadmap-anti-amyloid/"}]}}